Skip to content

TAGline November 2024

  • Jason Kirk

This year’s edition of TAGline takes stock of the state of the HIV, TB, and HCV pandemics worldwide, and advances bold visions for what a future without them must look like.

Read more

Gilead Deal to Expand Access to Lenacapavir for PrEP Falls Short

  • Jason Kirk

TAG recognizes Gilead Science’s announcement that it has issued six voluntary licenses to produce generic lenacapavir for distribution within 120 high HIV burden countries as a first step toward broadening access to this potent preventive drug for millions of people at risk of HIV.

Read more

2023 Annual Report

  • Jason Kirk

We're pleased to share with you our latest Annual Report, which highlights everything we accomplished in 2023.

Read more

Treatment Action Group Calls on NY City Council to Override and Mayor Adams to Reverse Egregious Cuts to New York City HIV Funding

  • Jason Kirk

In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.

Read more
Back To Top